Quantum Computing, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QUBT research report →
Range $10 – $22
Price Chart
About the company
Quantum Computing, Inc. (QUBT) is a Virginia-based technology firm dedicated to developing advanced software solutions for quantum computing. A cornerstone of their offerings is Qatalyst, a quantum application accelerator designed to empower developers.
- CEO
- Yuping Huang
- IPO
- 2007
- Employees
- 75
- HQ
- Hoboken, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a deep corrective regime, still well below its 200-day average of 8.39 and 50-day average of 7.13. It is trading near the 52-week low of 4.37 after a sharp pullback from the 14.45 high, which keeps the longer-term trend under pressure.
Street sentiment is constructive but not unanimous: the consensus is Buy with 3 Buy and 1 Hold ratings. The target stack has come down from earlier highs, with a 16 consensus target versus a 22 high and 10 low, while recent calls have been mixed between Neutral and Buy.
Earnings have been a modest beat story, with 5 of the last 8 quarters topping estimates. The next-year EPS view is still negative at -0.2833, so shareholders should watch whether revenue growth can keep improving while losses narrow from the current pace.
No notable discretionary insider buying or selling. Recent activity is dominated by award and vesting-related grants to the CEO, directors, and operating team, which reads as compensation flow rather than a directional signal.
Profitability remains weak, with a gross margin of -8.2% and operating margin of -4.544, while ROE is -2.65% and ROA is -4.26%. Revenue growth is still positive at 23.74%, and the balance sheet is strong with $1.118 billion in cash against just $1.8 million of debt.
QUBT sits in the speculative end of the quantum and photonics group, where revenue growth matters more than current earnings power. The setup favors a premium multiple only if commercialization scales; the current target consensus of 16 implies meaningful upside from the present market level.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $998.50M
- P/E
- -29.41
- Fwd P/E
- 12.94
- PEG
- 0.39
- P/S
- 52.72
- P/B
- 0.63
- EV/EBITDA
- -41.77
- Div Yield
- 0.00%
- Gross Margin
- -8.22%
- Op Margin
- -498.23%
- Net Margin
- -171.62%
- ROE
- -2.04%
- ROIC
- -5.86%
Latest fiscal year · YoY change
- Revenue
- $682.00K+82.8%
- Gross Profit
- $67.00K-40.2%
- Op Income
- $-51,077,000
- Net Income
- $-18,674,000+72.8%
- EPS
- $-0.11+84.9%
- OCF Growth
- -86.9%
- FCF Growth
- -66.2%
- 52W High
- $14.45
- 52W Low
- $4.37
- 50D MA
- $7.06
- 200D MA
- $8.37
- Beta
- 3.92
- RSI (14)
- 26
- Avg Volume
- 7.21M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Quantum Computing Inc. posted record quarterly revenue as photonics sales surged, while management emphasized that the company is shifting from technology development toward commercialization and scaled manufacturing.· November 9, 2026
- Q3 revenue was a record $9.5 million, up from $384 thousand a year ago, driven mainly by photonic products and recent acquisitions.
- Gross profit was $428 thousand, with gross margin of 4.5%, while operating expenses rose to $29 million and the company posted a $15.1 million net loss.
- Management said Dirac-3 has been released, with first customer shipment expected in Q4 and early feedback described as positive on capacity and solution quality.
- Backlog ended at about $39.1 million, and management said it typically converts over 12 to 18 months, though revenue and orders are lumpy.
- The company said it has about $1.3 billion in cash, cash equivalents, and investments, and reiterated no formal guidance while pointing to growth in backlog, orders, and manufacturing integration as key signs to watch.
Q3 revenue was $9.5 million, up from $384 thousand in the same period last year. Gross profit was $428 thousand, implying a gross margin of 4.5%. Operating expenses were $29 million versus $10.5 million a year ago, and net loss was $15.1 million, or $0.07 per basic share, versus net income of $2.4 million, or $0.01 per basic share, last year. Interest and other income was $13 million, up from $3.5 million. The company ended the quarter with approximately $1.3 billion in cash, cash equivalents, and investments, total assets of about $1.6 billion, liabilities of $47.7 million, and contract backlog of approximately $39.1 million. Management did not provide formal revenue or EPS guidance, but said liquidity is sufficient to fund operations for at least the next 12 months; it also said backlog typically burns off over 12 to 18 months, and that Q3 OpEx is a reasonable run rate for the next quarter with some natural increase from hiring.
Yuping Huang framed the quarter as evidence that QCI is moving from building technology to putting it into customer use, with execution now the central focus. He highlighted record revenue, early customer traction for Dirac-3, the ImmuBio collaboration, and the company’s broader photonics platform spanning computing, sensing, and communications. His tone was upbeat but cautious, repeatedly stressing that the company still has considerable work ahead and that adoption will take time across different markets.
Christopher Bruce Roberts focused on the financial step-up from the acquired photonics businesses, saying revenue of $9.5 million was largely driven by photonic products serving aerospace, government, and industrial applications. He noted gross margin was 4.5%, operating expenses were $29 million largely due to personnel growth and about $1 million of acquisition-related costs, and net loss was $15.1 million, offset in part by $13 million of interest and other income. He emphasized the balance sheet strength, citing about $1.3 billion in cash, cash equivalents, and investments, $916.9 million in working capital, and roughly $39.1 million of backlog, while saying the company has the resources to fund operations for at least 12 months and is planning $70 million to $80 million for Enhanced Fab 2 with spend mainly between now and March 31 next year.
Analysts pressed on Dirac-3 performance, backlog trends, commercialization milestones, the pace of manufacturing integration, international sales exposure, biotech/pharma expansion, and capital deployment. Management said Dirac-3 received positive early feedback, benchmarked well versus classical solvers such as Hexaly on the problems tested, and that the company expects first customer shipments in Q4, but it did not provide formal pipeline guidance. On backlog and revenue visibility, management said awards and revenue are lumpy, backlog typically converts over 12 to 18 months, and current OpEx is a reasonable near-term run rate; on capital allocation, it said several hundred million dollars are earmarked for CapEx, with Enhanced Fab 2 expected to require about $70 million to $80 million. Management also said it is not planning facility consolidation, but rather integrating operations across 11 facilities in 8 states and building synergies between them.
The bull case from the call is that QCI is showing tangible commercialization progress: revenue hit a record, backlog remains meaningful, and Dirac-3 appears to be creating real customer interest with positive benchmark results and a first shipment due in Q4. Management also argued that the acquired photonics businesses give the company a near-term revenue base while supporting longer-term quantum products, and that the balance sheet provides ample flexibility to invest without near-term financing pressure.
The main bear case is that profitability remains distant: gross margin was only 4.5%, operating expenses were far above gross profit, and the quarter still produced a $15.1 million net loss. Management also acknowledged that orders and deliveries are lumpy, backlog can fluctuate, and there is still considerable execution risk in integrating multiple acquisitions, scaling manufacturing, and proving that Dirac-3 and other quantum products can convert into sustained commercial demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.7%
- Shares Outstanding
- 226.93M
- Float Shares
- 201.18M
of shares held by institutions
345 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 17.23M | ▼ 506.17K |
| Vanguard Group Inc | 16.84M | ▲ 4.64M |
| Vanguard Capital Management LLC | 8.96M | ▲ 113.34K |
| Defiance Etfs, LLC | 7.03M | ▲ 2.54M |
| Penserra Capital Management LLC | 6.98M | ▲ 3.63M |
| Vanguard Portfolio Management LLC | 6.50M | ▼ 70.62K |
| Geode Capital Management, LLC | 5.41M | ▲ 84.52K |
| State Street Corp | 4.99M | ▲ 66.40K |
| Morgan Stanley | 3.82M | ▲ 532.32K |
| Mirae Asset Global Etfs Holdings Ltd. | 3.72M | ▲ 1.44M |
| Susquehanna International Group, Llp | 2.85M | ▲ 1.68M |
| Ubs Group AG | 2.51M | ▲ 463.84K |
Held by 272 ETFs
Biggest fund positions in QUBT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 20, 26 | Huang Yuping | other | 584,897 |
| Aug 20, 26 | Huang Yuping | other | 584,897 |
| Aug 20, 26 | Huang Yuping | other | 584,897 |
| Aug 20, 26 | Huang Yuping | other | 584,897 |
| Jul 17, 26 | Hunt Susan G. | other | 0 |
| May 28, 26 | Huang Yuping | other | 58,558 |
| May 28, 26 | Huang Yuping | other | 23,588 |
| May 28, 26 | Dianat Pouya | other | 9,979 |
| May 28, 26 | Dianat Pouya | other | 24,774 |
| May 28, 26 | Begliarbekov Milan | other | 9,979 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QUBT coverage
Recent articles, reports, and earnings notes.

Pasqal Holding S.A. IPO: The Bull Case Meets the Quantum Risk
Pasqal Holding S.A. is expected to list on Nasdaq on August 28, 2026 under PSQL, but the price range has not been disclosed. The setup pits fast revenue growth and a large quantum-computing opportunity against heavy losses, execution risk, and a still-early market.

Inside the Pasqal Holding SA IPO: Setup, Risks, and Verdict
Pasqal Holding SA Ordinary Share is expected to list on NASDAQ on 2026-08-28 under ticker PSQL. The company has not disclosed a price range or share count yet. The setup leans on real commercial traction, but investors should watch valuation, dilution, and whether quantum demand can keep scaling.

TF3 Revolution, Revealed: What Stock Is Marc Lichtenfeld Teasing in The Oxford Income Letter?
Marc Lichtenfeld and The Oxford Club's The Oxford Income Letter are pitching the "TF3 Revolution"; here's the company behind the $20 stock claim and what the filings support.
Want a deeper read on QUBT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Quantum Computing Looks Ideal For Tax-Loss Harvesting (Rating Downgrade)
seekingalpha.com · Nov 18
Quantum Computing Inc. Announces Participation in Upcoming December Investor Conferences
prnewswire.com · Nov 17
D-Wave Quantum Falls 7% as Post-Earnings Selloff Deepens on Weak Bookings; IonQ Sinks 8%, Rigetti Slides 5%
247wallst.com · Nov 16
IonQ Falls 8% as Quantum Computing Stocks Slide; Rigetti Drops 6%, D-Wave Declines 4%
247wallst.com · Nov 13
Rigetti Falls 5% After CEO Admits Quantum Can’t Yet Prove ROI; IonQ Sinks 8%, D-Wave Slides 5%
247wallst.com · Nov 12
IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
marketbeat.com · Nov 11
Rigetti Drops 5% on Revenue Miss and Soft 2026 Outlook; IonQ Slides 2%, D-Wave Rises 2%
247wallst.com · Nov 11
QUBT Q3 Earnings Call Focuses on Commercial Growth & Scaling
zacks.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 21, 2026 · Live quote · Not investment advice